NEW
YORK, July 11, 2022 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com),
a clinical-stage pharmaceutical company focused on the development
of oral drug delivery systems, announced today that it will present
an in-person company overview and share the Company's latest
updates at the Canaccord Genuity Annual Growth Conference, to
be held in Boston, Massachusetts
from August 8-11, 2022.
Presentation Details:
Canaccord Genuity Annual Growth Conference
Date:
Wednesday, August 10, 2022
Time:
4:30 p.m. E.T.
Location:
InterContinental Boston Hotel, 510 Atlantic Avenue, Boston, Massachusetts
The presentation will be webcasted. The link to view the
presentation will be uploaded to the Oramed website
(www.oramed.com) 48 hours before the event and will be available
for 90 days following the presentation.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform
technology pioneer in the field of oral delivery solutions for
drugs currently delivered via injection. Established in 2006, with
offices in the United States and Israel, Oramed has
developed a novel Protein Oral Delivery (POD™) technology. Oramed
is seeking to transform the treatment of diabetes through its
proprietary lead candidate, ORMD-0801, which is being
evaluated in two pivotal Phase 3 studies and has the potential to
be the first commercial oral insulin capsule for the treatment
of diabetes. In addition, Oramed is developing an oral GLP-1
(Glucagon-like peptide-1) analog capsule.
For more information, please visit www.oramed.com
Company Contact
Zach Herschfus
+1-844-9-ORAMED
zach@oramed.com
Logo -
https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/oramed-to-present-at-the-upcoming-canaccord-genuity-annual-growth-conference-301583656.html
SOURCE Oramed Pharmaceuticals Inc.